C4X CEO discusses landmark Indivior deal

Clive Dix, Chief Executive of C4X Discovery Holdings plc (LON:C4XD), discusses with Proactive’s Andrew Scott their licensing deal with FTSE 250-listed Indivior for its addiction behaviour suppressant, C4X3256.

It is the first major partnership for C4X, which will receive US$10mn up front and a further US$284mn dependent on how successful the drug proves.